¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"direct fluorescent antibody technique"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • labeled antibody
    Ç¥ÁöÇ×ü
  • mitochondrial antibody
    ¹ÌÅäÄܵ帮¾ÆÇ×ü, »ç¸³Ã¼Ç×ü
  • monoclonal antibody
    ´ÜŬ·ÐÇ×ü
  • monovalent antibody
    Àϰ¡Ç×ü
  • multivalent antibody
    ´Ù°¡Ç×ü
  • maternal antibody
    ¸ðüÇ×ü
  • neutralizing antibody
    ÁßÈ­Ç×ü
  • nonprecipitating antibody
    ºñħÀüÇ×ü
  • normal antibody
    Á¤»óÇ×ü
  • natural antibody
    ÀÚ¿¬Ç×ü
  • polyclonal antibody
    ´ÙŬ·ÐÇ×ü
  • polyvalent antibody
    ´Ù°¡Ç×ü
  • precipitating antibody
    ħÀüÇ×ü
  • protective antibody
    ¹æ¾îÇ×ü
  • radioimmunoprecipitating antibody
    ¹æ»ç¸é¿ªÄ§ÀüÇ×ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • maternal antibody
    ¸ðüÇ×ü
  • mitochondrial antibody
    ¹ÌÅäÄܵ帮¾ÆÇ×ü, »ç¸³Ã¼Ç×ü
  • monoclonal antibody
    ´ÜŬ·ÐÇ×ü
  • monovalent antibody
    Àϰ¡Ç×ü
  • multivalent antibody
    ´Ù°¡Ç×ü
  • natural antibody
    ÀÚ¿¬Ç×ü
  • neutralizing antibody
    ÁßÈ­Ç×ü
  • nonprecipitating antibody
    ºñħÀüÇ×ü
  • polyclonal antibody
    ´ÙŬ·ÐÇ×ü
  • polyvalent antibody
    ´Ù°¡Ç×ü
  • precipitating antibody
    ħÀüÇ×ü
  • protective antibody
    ¹æ¾îÇ×ü
  • radioimmunoprecipitating antibody
    ¹æ»ç¸é¿ªÄ§ÀüÇ×ü
  • reaginic antibody
    Áï½ÃÇü°ú¹ÎÇ×ü
  • secretory antibody
    ºÐºñÇ×ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • heterophil antibody
    ÀÌÁ¾Ä£È­¼º Ç×ü
  • heterophil(e) antibody
    ÀÌÁ¾Ä£È­(¼º)Ç×ü(ì¶ðúöÑûùàõù÷ô÷).
  • heterophil(e) antibody reaction
    ÀÌÁ¾Ä£È­(¼º) Ç×ü¹ÝÀÀ(¡­Úãëë).
  • heterophil(e) antibody test
    ÀÌÁ¾Ä£È­¼º Ç×ü½ÃÇè.
  • homocytotropic antibody
    µ¿Á¾¼¼Æ÷ģȭ¼º Ç×ü.
  • homologous antibody
    »óµ¿Ç×ü.
  • hybrid antibody molecule
    ÇÏÀ̺긮µåÇ×üºÐÀÚ
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • hypersensitivity, antibody-mediated
    Ç×ü¸Å°³ °ú¹Î¹ÝÀÀ
  • immobilizing antibody
    ¿îµ¿¾ïÁ¦Ç×ü.
  • incomplete antibody
    ºÒ¿ÏÀüÇ×ü.
  • incomplete antibody
    ºÒ¿ÏÀüÇ×ü
  • indirect immunofluorescence antibody
    °£Á¢¸é¿ªÇü±¤Ç×ü
  • inhibiting antibody
    ¾ïÁ¦Ç×ü.
  • instructive theory of antibody production
    Áö·É¼³ (Ç×ü»ý»ê)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • technique, play
    ³îÀ̱â¹ý.
  • three field isocentric technique
    »ï¿µ¿ªµîÁß½ÉÁ¶»ç¹ý
  • transfontanelle technique
    °æÃµ¹® ±â¹ý
  • transmastoid translabyrinthine technique
    °æÀ¯µ¹¹Ì·ÎÁ¢±Ù(¹ý)
  • turbidometric technique
    ȥʵµÃøÁ¤±â¹ý
  • two field technique
    ÀÌ¿ªÁ¶»ç¹ý
  • two voltage testing technique
    ÀÌÀü¾Ð½ÃÇè¹ý
  • ultrasonic technique
    ÃÊÀ½ÆÄ ±â¹ý
  • utilization technique
    ÀÌ¿ë±â¼ú.
  • van Lint technique
    ¹Ý¸°Æ®¹ý
  • variable bandwidth technique
    ´Ùº¯ Á֯ļöÆø ±â¹ý
  • volume gradient echo technique
    ¿ëÀû °æ»ç ¿¡ÄÚ ±â¹ý
  • zymotechnic =zymo technique
    ¹ßÈ¿ÇÐ(Û£ý£ùÊ).
  • acetylcholine receptor antibody
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëüÇ×ü
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
FRAT free radical assay technique
IP icterus praecox; imaging plate; immune precipitate; immunoblastic plasma; immunoperoxidase technique...
IPT immunoperoxidase technique; immunoprecipitation; interpersonal psychotherapy; isoproterenol
LMT left mentotransverse [fetal position]; leukocyte migration technique
MART multiplicative algebraic reconstruction technique
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
SIF Small Intensely Fluorescent
YFP Yellow Fluorescent Protein
BFP blue fluorescent protein
CFP cyan fluorescent protein
EYFP enhanced yellow fluorescent protein
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
heterospecific antibody <immunology> Artificially produced antibody in which the two antigen binding sites are for different antigens.
(18 Nov 1997)
secondary antibody deficiency Immunodeficiency in which there is no evident defect in the lymphoid tissues, but rather hypercatabolism or loss of immunoglobulins such as occurs in familial idiopathic hypercatabolic hypoproteinaemia or in defects associated with the nephrotic syndrome.
Synonym: secondary agammaglobulinaemia, secondary antibody deficiency, secondary hypogammaglobulinaemia.
(05 Mar 2000)
secondary antibody response An antibody made upon second (subsequent) exposure to an antigen, mostly of the class IgG.
(09 Oct 1997)
homocytotropic antibody <immunology> A type of antibody which is able to attach itself to the surfaces of cells without needing specific combining sites. A homocytotropic antibody will only bind to cells which are from the same species as itself.
(09 Oct 1997)
hybrid antibody <immunology> Artificially produced antibody made by fusing hybridomas producing two different antibodies, the hybrid cells produce three different antibodies, only one of which is a heterophilic antibody. Can also be prepared chemically from two antibodies.
(18 Nov 1997)
hyperimmune antibody An antibody which occurs in a hyperimmune individual and which targets the antigen that has brought on the hyperimmunity.
(09 Oct 1997)
natural antibody Antibody demonstrable in the serum or plasma of various persons or animals not known to have been stimulated by specific antigen, either artificially or as the result of naturally occurring contact.
Synonym: natural antibody.
(05 Mar 2000)
neutralizing antibody A form of antibody that reacts with an infectious agent (usually a virus) and destroys or inhibits its infectivity and virulence; may be demonstrated by means of mixing serum with the suspension of infectious agent, and then injecting the mixture into animals or cell cultures that are susceptible to the agent in question.
(05 Mar 2000)
nonprecipitable antibody Antibody that, under conditions normally employed in precipitin tests, is refractory to precipitation by specific antibody, demonstrable when antigen is added serially in small amounts; nonprecipitating antibody will precipitate under special conditions such as addition of complement.
Synonym: nonprecipitable antibody.
(05 Mar 2000)
nonprecipitating antibody Antibody that, under conditions normally employed in precipitin tests, is refractory to precipitation by specific antibody, demonstrable when antigen is added serially in small amounts; nonprecipitating antibody will precipitate under special conditions such as addition of complement.
Synonym: nonprecipitable antibody.
(05 Mar 2000)
normal antibody Antibody demonstrable in the serum or plasma of various persons or animals not known to have been stimulated by specific antigen, either artificially or as the result of naturally occurring contact.
Synonym: natural antibody.
(05 Mar 2000)
syndrome, antiphospholipid antibody An immune disorder characterised by the presence of abnormal antibodies in the blood associated with certain medical conditions including abnormal blood clotting, migraine headaches, premature miscarriage, and low blood platelet counts (thrombocytopenia).
(12 Dec 1998)
double antibody immunoassay A method of separating antibody-bound antigen (e.g., insulin) from free antigen by precipitating the former with antibody specific for immunoglobulin.
Synonym: double antibody immunoassay, double antibody method.
(05 Mar 2000)
double antibody method A method of separating antibody-bound antigen (e.g., insulin) from free antigen by precipitating the former with antibody specific for immunoglobulin.
Synonym: double antibody immunoassay, double antibody method.
(05 Mar 2000)
double antibody precipitation A method of separating antibody-bound antigen (e.g., insulin) from free antigen by precipitating the former with antibody specific for immunoglobulin.
Synonym: double antibody immunoassay, double antibody method.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
ÅëÇÕ°Ë»ö ¿Ï·á